Chronic Obstructive Pulmonary Disease Treatment Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 - 2030
CHAPTER 1. Industry Overview of Chronic Obstructive Pulmonary Disease Treatment Market
1.1. Definition and Scope
1.1.1. Definition of Chronic Obstructive Pulmonary Disease Treatment
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Chronic Obstructive Pulmonary Disease Treatment Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Chronic Obstructive Pulmonary Disease Treatment Market By Drug Class
1.2.3. Chronic Obstructive Pulmonary Disease Treatment Market By Distribution Channel
1.2.4. Chronic Obstructive Pulmonary Disease Treatment Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Chronic Obstructive Pulmonary Disease Treatment Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Chronic Obstructive Pulmonary Disease Treatment Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Chronic Obstructive Pulmonary Disease Treatment Market By Drug Class
4.1. Introduction
4.2. Chronic Obstructive Pulmonary Disease Treatment Revenue By Drug Class
4.2.1. Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast, By Drug Class, 2018-2030
4.2.2. Bronchodilators
4.2.2.1. Bronchodilators Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.3. Phosphodiesterase Type 4 Inhibitors
4.2.3.1. Phosphodiesterase Type 4 Inhibitors Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.4. Combination
4.2.4.1. Combination Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.5. Corticosteroids
4.2.5.1. Corticosteroids Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.6. Mucokinetics
4.2.6.1. Mucokinetics Market Revenue (USD Million) and Growth Rate (%), 2018-2030
4.2.7. Others
4.2.7.1. Others Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 5. Chronic Obstructive Pulmonary Disease Treatment Market By Distribution Channel
5.1. Introduction
5.2. Chronic Obstructive Pulmonary Disease Treatment Revenue By Distribution Channel
5.2.1. Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast, By Distribution Channel, 2018-2030
5.2.2. Hospital Pharmacies
5.2.2.1. Hospital Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.3. Online Pharmacies
5.2.3.1. Online Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2018-2030
5.2.4. Retail Pharmacies
5.2.4.1. Retail Pharmacies Market Revenue (USD Million) and Growth Rate (%), 2018-2030
CHAPTER 6. North America Chronic Obstructive Pulmonary Disease Treatment Market By Country
6.1. North America Chronic Obstructive Pulmonary Disease Treatment Market Overview
6.2. U.S.
6.2.1. U.S. Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
6.2.2. U.S. Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
6.3. Canada
6.3.1. Canada Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
6.3.2. Canada Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
6.4. North America PEST Analysis
CHAPTER 7. Europe Chronic Obstructive Pulmonary Disease Treatment Market By Country
7.1. Europe Chronic Obstructive Pulmonary Disease Treatment Market Overview
7.2. U.K.
7.2.1. U.K. Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.2.2. U.K. Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
7.3. Germany
7.3.1. Germany Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.3.2. Germany Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
France
7.3.3. France Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.3.4. France Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
7.4. Spain
7.4.1. Spain Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.4.2. Spain Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
7.5. Rest of Europe
7.5.1. Rest of Europe Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
7.5.2. Rest of Europe Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
7.6. Europe PEST Analysis
CHAPTER 8. Asia Pacific Chronic Obstructive Pulmonary Disease Treatment Market By Country
8.1. Asia Pacific Chronic Obstructive Pulmonary Disease Treatment Market Overview
8.2. China
8.2.1. China Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.2.2. China Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
8.3. Japan
8.3.1. Japan Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.3.2. Japan Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
8.4. India
8.4.1. India Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.4.2. India Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
8.5. Australia
8.5.1. Australia Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.5.2. Australia Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
8.6. South Korea
8.6.1. South Korea Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.6.2. South Korea Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
8.7.2. Rest of Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America Chronic Obstructive Pulmonary Disease Treatment Market By Country
9.1. Latin America Chronic Obstructive Pulmonary Disease Treatment Market Overview
9.2. Brazil
9.2.1. Brazil Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.2.2. Brazil Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
9.3. Mexico
9.3.1. Mexico Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.3.2. Mexico Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
9.4. Rest of Latin America
9.4.1. Rest of Latin America Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
9.4.2. Rest of Latin America Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
9.5. Latin America PEST Analysis
CHAPTER 10. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market By Country
10.1. Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market Overview
10.2. GCC
10.2.1. GCC Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.2.2. GCC Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
10.3. South Africa
10.3.1. South Africa Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.3.2. South Africa Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Drug Class, 2018-2030
10.4.2. Rest of Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Revenue (USD Million) and Forecast By Distribution Channel, 2018-2030
10.5. Middle East & Africa PEST Analysis
CHAPTER 11. Player Analysis Of Chronic Obstructive Pulmonary Disease Treatment Market
11.1. Chronic Obstructive Pulmonary Disease Treatment Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Chronic Obstructive Pulmonary Disease Treatment Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. Company Profile
12.1. Orion Corporation
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (USD Million), 2021
12.1.3.2. Orion Corporation 2021 Chronic Obstructive Pulmonary Disease Treatment Business Regional Distribution
12.1.4. Product/Service and Specification
12.1.5. Recent Developments & Business Strategy
12.2. Mylan N.V.
12.3. AstraZeneca
12.4. Teva Pharmaceutical Industries Ltd.
12.5. BoehringerIngelheim Pharmaceuticals, Inc.
12.6. Novartis AG
12.7. GlaxoSmithKline plc
12.8. CHIESI Farmaceutici S.p.A.
12.9. Sunovion Pharmaceuticals, Inc.
Frequently Asked Questions
What is the size of global chronic obstructive pulmonary disease treatment market in 2021?
The estimated value of global chronic obstructive pulmonary disease treatment market in 2021 was accounted to be USD 16,784 Million.
What is the CAGR of global chronic obstructive pulmonary disease treatment market during forecast period of 2022 to 2030?
The projected CAGR chronic obstructive pulmonary disease treatment market during the analysis period of 2022 to 2030 is 4.9%.
Which are the key players operating in the market?
The prominent players of the global chronic obstructive pulmonary disease treatment market are Orion Corporation, Mylan N.V., AstraZeneca, Teva Pharmaceutical Industries Ltd., BoehringerIngelheim Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., and Sunovion Pharmaceuticals, Inc.
Which region held the dominating position in the global chronic obstructive pulmonary disease treatment market?
North America held the dominating chronic obstructive pulmonary disease treatment during the analysis period of 2022 to 2030.
Which region registered the fastest growing CAGR for the forecast period of 2022 to 2030?
Asia-Pacific region exhibited fastest growing CAGR for chronic obstructive pulmonary disease treatment during the analysis period of 2022 to 2030.
What are the current trends and dynamics in the global chronic obstructive pulmonary disease treatment market?
Growth in the prevalence of COPD and increasing rates of cigarette consumption among young individuals drives the growth of global chronic obstructive pulmonary disease treatment market.
By distribution channel segment, which sub-segment held the maximum share?
Based on distribution channel, hospital pharmacies segment is expected to hold the maximum share of the chronic obstructive pulmonary disease treatment market.
Select Licence Type
Connect with our sales team
Why Acumen Research And Consulting
100%
Customer Satisfaction
24x7
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
